Electroconvulsive therapy in patients with Huntington's disease and depression;Elektroconvulsietherapie bij patiënten met de ziekte van Huntington en depressie

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 39, 2005, Pages 2141-2144

  Van Duijn, E ^a   Roos, R A C ^b   Smarius, L J C A ^b   Van Der Mast, R C ^b  

^a GGZ Duin en Bollenstreek ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; LITHIUM CARBONATE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; PREVALENCE; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME;

DEPRESSIVE DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 25444503800     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Huntington G. On chorea. Med Surg Rep 1872;26:320-1.
2. Naarding P, Kremer HPH, Zitman FG. Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry 2001;16:439-45.
3. Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Suicide risk in Huntington's disease. J Med Genet 1993;30:293-5.
4. Broek WW van den, Huyser J, Koster AM, Leentjes AFG, Stek M, Thewissen ML, et al. Richtlijn Elektroconvulsietherapie. Amsterdam: Boom; 2000.
5. Landelijke stuurgroep multidisciplinaire richtlijnontwikkeling in de GGZ. Multidisciplinaire richtlijn Depressie. Utrecht: Trimbos-instituut; 2005.
6. Folstein SE, Abbott MH, Chase GA, Jensen BA, Folstein MF. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 1983;13:537-42.
7. Patel SV, Tariot PN, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry 1996;8:23-6.
8. Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother 2003;37:452.
9. Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatry 1986;149:654-6.
10. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996;8:338-40.
11. Como PG, Rubin AJ, O'Brien CF, Lawler K, Hickey Ch, Rubin AE, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997;12:397-401.
12. Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 1994;6: 154-9.
13. Evans DL, Pedersen CA, Tancer ME. ECT in the treatment of organic psychosis in Huntington's disease. Convuls Ther 1987;3:145-50.
14. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington's disease. J Neuropsychiatry Clin Neurosci 1996;8: 209-10.
15. Leroi I, Michalon M. Early psychiatric manifestations of Huntington's disease: more than just a movement disorder. Dalhousie Medical Journal 1997;2 [on-linetijdschrift].
16. Kennedy R, Mittal D, O'Jile J. Electroconvulsive therapy in movement disorders: an update. J Neuropsychiatry Clin Neurosci 2003;15: 407-21.
17. Witjes-Ané MNW, Zwinderman AH, Tibben A, Ommen GJB van, Roos RAC. Behavioural complaints in participants who underwent predictive testing for Huntington's disease. J Med Genet 2002;39: 857-62.
18. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-42.
19. Nehl C, Paulsen JS. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. Huntington Study Group. J Nerv Ment Dis 2004;192:72-4.
20. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981; 31:1333-5.
21. Cangemi jr CF, Miller RT. Huntington's disease: review and anesthetic case management. Anesth Prog 1998;45:150-3.